The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients

References

• Walker U, Tyndall A, Czirjak L, et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis. 2009;68(6):856–862.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Airo P, et al. Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis. 2007;66(2):257–259.
   PubMed Web of Science ®Google Scholar
• Koumakis E, Wipff J, Dieudé P, et al. TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. Ann Rheum Dis. 2012;71(11):1900–1903.
   PubMed Web of Science ®Google Scholar
• Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res Ther. 2002;4(6):R11.
   Google Scholar
• Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26(11):587–595.
   PubMed Web of Science ®Google Scholar
• Zanatta E, Codullo V, Avouac J, et al. Systemic sclerosis: recent insight in clinical management. Joint Bone Spine. 2020;87(4):293–299.
   PubMed Web of Science ®Google Scholar
• Elhai M, Meune C, Boubaya M, et al., Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 76(11): 1897–1905. 2017.
   PubMed Web of Science ®Google Scholar
• Tyndall A, Ladner UM, Matucci-Cerinic M. The EULAR Scleroderma Trials and Research group (EUSTAR): an international framework for accelerating scleroderma research. Curr Opin Rheumatol. 2008;20(6):703–706.
   PubMed Web of Science ®Google Scholar
• Steele R, Dunne J, Johnson SR, et al. Improving the sensitivity of the American college of rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol. 2007;25:754–757.
   PubMed Web of Science ®Google Scholar
• Patel S, Morrisroe K, Proudman S, et al. Occupational silica exposure in an Australian systemic sclerosis cohort. Rheumatology (Oxford). 2020;1–6.
   Web of Science ®Google Scholar
• Dougherty DH, Kwakkenbos L, Carrier M-E, et al. The scleroderma patient-centered intervention network cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology (Oxford). 2018;57(9):1623–1631.
   PubMed Web of Science ®Google Scholar
• Morgan ND, Shah AA, Mayes MD, et al. Clinical and serological features of systemic sclerosis in a multicenter African American cohort: analysis of the genome research in African American scleroderma patients clinical database. Medicine (Baltimore). 2017;96(51):51.
   Web of Science ®Google Scholar
• Müller-Ladner U, Tyndall A, Czirjak L, et al. Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved? Ann Rheum Dis. 2014;73(2):324–327.
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold A-M, Distler O, Murray B, et al. Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open. 2019;5(1):e000826.
   PubMed Web of Science ®Google Scholar
• Avouac J, Fransen J, Walker U, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR Scleroderma Trials and Research group. Ann Rheum Dis. 2011;70(3):476–481.
   PubMed Web of Science ®Google Scholar
• Minier T, Guiducci S, Bellando-Randone S, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014;73(12):2087–2093.
   PubMed Web of Science ®Google Scholar
• Randone SB, Lepri G, Husher D, et al. OP0065 The Very Early Diagnosis of Systemic Sclerosis (VEDOSS) project: predictors to develop definite disease from an international multicentre study. Ann Rheum Dis. 2019;78:104–105.
   Web of Science ®Google Scholar
• Wirz EG, Jaeger VK, Allanore Y, et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2016;75(7):1285–1292.
   PubMed Web of Science ®Google Scholar
• Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016;11(10):e0163894.
   PubMed Web of Science ®Google Scholar
• Dobrota R, Maurer B, Graf N, et al. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Ann Rheum Dis. 2016;75(10):1743–1748.
   PubMed Web of Science ®Google Scholar
• Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71(8):1355–1360.
   PubMed Web of Science ®Google Scholar
• Walker U, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66(6):754–763.
   PubMed Web of Science ®Google Scholar
• Hügle T, Schuetz P, Daikeler T, et al. Late-onset systemic sclerosis—a systematic survey of the EULAR scleroderma trials and research group database. Rheumatology (Oxford). 2011;50(1):161–165.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Tyndall A, Zulian F, et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology (Oxford). 2012;51(10):1832–1837.
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Boracchi P, Gualtierotti R, et al. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: a EUSTAR exploratory study. Microvasc Res. 2015;102:19–24.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Klotsche J, Torok KS, et al. Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. J Scleroderma Relat Disord. 2019;4(1):49–61.
   Web of Science ®Google Scholar
• Maurer B, Graf N, Michel BA, et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis. 2015;74(6):1124–1131.
   PubMed Web of Science ®Google Scholar
• Wu W, Jordan S, Graf N, et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 2019;78(5):648–656.
   PubMed Web of Science ®Google Scholar
• Elhai M, Avouac J, Walker UA, et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016;75(1):163–169.
   PubMed Web of Science ®Google Scholar
• Peoples C, Medsger JTA, Lucas M, et al. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Relat Disord. 2016;1(2):204–212.
   Web of Science ®Google Scholar
• Allanore Y, Meune C, Vonk M, et al., Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 69(1): 218–221. 2010.
   PubMed Web of Science ®Google Scholar
• Avouac J, Walker U, Tyndall A, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research group (EUSTAR) database. J Rheumatol. 2010;37(7):1488–1501.
   PubMed Web of Science ®Google Scholar
• Avouac J, Walker UA, Hachulla E, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016;75(1):103–109.
   PubMed Web of Science ®Google Scholar
• Mihai C, Landewé R, Van Der Heijde D, et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis. 2016;75(4):681–686.
   PubMed Web of Science ®Google Scholar
• Becker M, Graf N, Sauter R, et al. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Ann Rheum Dis. 2019;78(9):1242–1248.
   PubMed Web of Science ®Google Scholar
• Allanore Y. Limited cutaneous systemic sclerosis: the unfairly neglected subset. J Scleroderma Relat Disord. 2016;1(3):241–246.
   Web of Science ®Google Scholar
• Frantz C, Huscher D, Avouac J, et al. Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database. Autoimmun Rev. 2020;19(2):102452.
   PubMed Web of Science ®Google Scholar
• Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33(9):1789–1801.
   PubMed Web of Science ®Google Scholar
• Volkmann ER. Natural history of systemic sclerosis–related interstitial lung disease: how to identify a progressive fibrosing phenotype. J Scleroderma Relat Disord. 2020;5(2_suppl):31–40.
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold A-M, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2020;annrheumdis-2020-217455. DOI:10.1136/annrheumdis-2020-217455.
   Google Scholar
• Kuwana M, Azuma A. Nintedanib: new indication for systemic sclerosis-associated interstitial lung disease. Mod Rheumatol. 2020;30(2):225–231.
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528.
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold A-M, Maher TM, Philpot EE, et al., The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2(2): e71–83. 2020. .
   PubMedGoogle Scholar
• Sandmeier B, Jäger VK, Nagy G, et al. Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S75–9.
   PubMed Web of Science ®Google Scholar
• Proudman SM, Huq M, Stevens W, et al. What have multicentre registries across the world taught us about the disease features of systemic sclerosis? J Scleroderma Relat Disord. 2017;2(3):169–182.
   Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–1815.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007;66(7):940–944.
   PubMed Web of Science ®Google Scholar
• Hachulla E, Clerson P, Airò P, et al. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology (Oxford). 2015;54(7):1262–1269.
   PubMed Web of Science ®Google Scholar
• Valentini G, Bencivelli W, Bombardieri S, et al. European Scleroderma Study group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis. 2003;62(9):901–903.
   PubMed Web of Science ®Google Scholar
• Valentini G, Iudici M, Walker UA, et al., The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 76(1): 270–276. 2017. .
   PubMed Web of Science ®Google Scholar
• Fasano S, Riccardi A, Messiniti V, et al. Revised European Scleroderma Trials and Research group activity index is the best predictor of short-term severity accrual. Ann Rheum Dis. 2019;78(12):1681–1685.
   PubMed Web of Science ®Google Scholar
• Lazzaroni M-G, Cavazzana I, Colombo E, et al. Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol. 2017;44(5):639–647.
   PubMed Web of Science ®Google Scholar
• Schneeberger D, Tyndall A, Kay J, et al. Systemic sclerosis without antinuclear antibodies or Raynaud’s phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford). 2013;52(3):560–567.
   PubMed Web of Science ®Google Scholar
• Wipff J, Coriat R, Masciocchi M, et al. Outcomes of Barrett’s oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. Rheumatology (Oxford). 2011;50(8):1440–1444.
   PubMed Web of Science ®Google Scholar
• Ghrénassia E, Avouac J, Khanna D, et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol. 2014;41(1):99–105.
   PubMed Web of Science ®Google Scholar
• Jaeger VK, Distler O, Maurer B, et al. Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology (Oxford). 2018;57(3):441–450.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Bozzi S, Terlinden A, et al. Health assessment questionnaire-disability index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Res Ther. 2020;(in print). DOI:10.21203/rs.3.rs-38370/v2.
   Google Scholar
• Zanatta E, Colombo C, D’Amico G, et al. Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases. Int J Mol Sci. 2019;20(22):5563.
   Web of Science ®Google Scholar
• Matucci‐Cerinic M, Kahaleh B, Wigley FM. Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65(8):1953–1962.
   PubMed Web of Science ®Google Scholar
• Foocharoen C, Tyndall A, Hachulla E, et al. Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. Arthritis Res Ther. 2012;14(1):R37.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–628.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339.
   PubMed Web of Science ®Google Scholar
• Valentini G, Huscher D, Riccardi A, et al., Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis. 78(11): 1576–1582. 2019.
   PubMed Web of Science ®Google Scholar
• Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188–1194.
   PubMed Web of Science ®Google Scholar
• Elhai M, Boubaya M, Distler O, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78(7):979–987.
   PubMed Web of Science ®Google Scholar
• Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72(7):1217–1220.
   PubMed Web of Science ®Google Scholar
• Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57(12):2106–2113.
   PubMed Web of Science ®Google Scholar
• Khanna D, Jahreis A, Furst DE. Tocilizumab treatment of patients with systemic sclerosis: clinical data. J Scleroderma Relat Disord. 2017;2(2_suppl):S29–35.
   Web of Science ®Google Scholar
• Castellví I, Elhai M, Bruni C, et al. Safety and effectiveness of abatacept in systemic sclerosis: the EUSTAR experience. Semin Arthritis Rheum. 2020. (Online ahead of print). DOI:10.1016/j.semarthrit.2019.12.004.
   Web of Science ®Google Scholar
• Khanna D, Spino C, Johnson S, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a Phase II investigator‐initiated, multicenter, double‐blind, randomized, placebo‐controlled trial. Arthritis Rheumatol. 2020;72(1):125–136.
   PubMed Web of Science ®Google Scholar
• Distler JH, Jordan S, Airo P, et al. Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S40–5.
   PubMed Web of Science ®Google Scholar
• Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: state of the art. Autoimmun Rev. 2018;17(9):882–889.
   PubMed Web of Science ®Google Scholar
• Bütikofer L, Varisco PA, Distler O, et al. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis. Arthritis Res Ther. 2020;22(1):1–9.
   PubMed Web of Science ®Google Scholar
• Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: navigating recommendations and guidelines. Semin Arthritis Rheum. 2017;46(6):767–774.
   PubMed Web of Science ®Google Scholar
• Rossi D, Zanatta E, Marson P, et al. How I treat patients with systemic sclerosis in clinical practice. Autoimmun Rev. 2017;16(10):1024–1028.
   PubMed Web of Science ®Google Scholar
• Smith V, Scirè CA, Talarico R, et al. Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open. 2019;4(Suppl 1):e000782.
   Google Scholar
• Bruni C, Frech T, Manetti M, et al. Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed? Front Immunol. 2018;9:2045.
   PubMed Web of Science ®Google Scholar